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Objective: The aim was to prospectively analyze all-cause mortality, predictors of
survival, and late functional results after myocardial revascularization for ischemic
cardiomyopathy over a 10-year follow-up.
Methods: We prospectively studied 57 patients with stable coronary artery disease
and poor left ventricular ejection function (35%), enrolled between 1989 and
1994. Stress thallium was analyzed in 37 patients to identify reversible ischemia. To
avoid patients with a stunned myocardium, we excluded those with unstable angina
or myocardial infarction within the previous 4 weeks. Mean age of the patients was
67  8 years, and 93% of patients were men. Mean left ventricular ejection fraction
was 0.28 0.04, 50% were in Canadian Cardiovascular Society angina class III-IV,
and 65% were in New York Heart Association functional class III-IV.
Results: Operative mortality was 1.7% (1/57). The mean left ventricular ejection
fraction (0.30) at 15 months postoperatively did not change from before operation
(0.28, P  .09). There were 8 deaths at 1 year and 42 deaths over the course of the
study, producing a survival of 82.5% at 1 year, 55.7% at 5 years, and 23.9% at 10
years (95% confidence interval: 14.6%-39.1%). Symptom-free survival was 77.2%
at 1 year and 20.3% at 10 years. The leading cause of death was heart failure in 29%
(12/42). Multivariate analysis showed that large reversible defects on stress thallium
were associated with improved left ventricular ejection fraction at 1 year (P  .01)
but only male sex was associated with improved long-term survival (P  .036).
Conclusions: Myocardial revascularization for ischemic cardiomyopathy is associ-
ated with good functional relief from the symptoms of angina initially and, to a
lesser extent, heart failure. Revascularization may have the advantage of preserving
the remaining left ventricular function. However, the long-term mortality remains
high.
Patients with coronary artery disease and severe left ventricular (LV)dysfunction have a poor prognosis, with limited survival and func-tional improvement, when treated medically.1-6 Transplantation is aneffective treatment option but limited by availability of donors. Itreadily became apparent that a proportion of patients with end-stageischemic heart disease could be offered myocardial revascularization
with an early outcome comparable with transplantation.5-9 Progress in the field of
imaging and metabolic diagnostic techniques, as well as advances in intraoperative
myocardial protection and postoperative care, have led to a significant decrease in
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operative risk over recent years.10-13 However, there are few
reports in the literature on long-term survival and symptom-
atic status in this group of patients.14-16
We have reported short-term outcomes for patients with
severe LV dysfunction undergoing coronary artery bypass
grafting (CABG).12 This study reports the results of pro-
spective 10-year follow-up on survival and relief from an-
gina and heart failure in these patients.
Patients and Methods
Patients with stable coronary artery disease suitable for CABG and
impaired LV function (LV ejection fraction [LVEF]  0.35 on
radionuclide ventriculography [RNVG]) were prospectively en-
tered into the study between June 1989 and June 1994. Patients
with unstable angina, myocardial infarction, and other significant
ischemic events within 4 weeks of surgery were specifically ex-
cluded. Those requiring repeat CABG or concomitant procedures
(including valvular operation and aneurysmectomy) were also
excluded. Patients with left main coronary artery stenosis of 50%
or more were not included because of the risk involved from
investigational stress testing. Of 1708 patients undergoing primary
coronary surgery over the entry period, 234 patients fulfilled the
above criteria and had impaired LV function on contrast left
ventriculography. Of these, 57 patients had an LVEF 0.35 or less
on RNVG and were enrolled in the study. The protocol was
approved by the Austin Hospital Ethics Committee for Human
Research. Written informed consent of all the enrolled patients was
obtained including specific consent for thallium and RNVG stud-
ies.
Coronary Revascularization
All patients underwent CABG under mild hypothermic (34°C)
cardiopulmonary bypass using a membrane oxygenator. In all
cases, distal anastomoses between the bypass grafts and native
coronary arteries were performed under aortic crossclamping on a
heart arrested by blood cardioplegic solution infused at room
temperature. In the initial part of the study, cardioplegic solution
was given antegradely. The proximal ends of vein grafts were then
anastomosed to the aorta during partial exclusion. As retrograde
coronary sinus cardioplegia became more popular, this technique
was adopted in patients enrolled in the latter part of the study. All
patients had proximal anastomoses completed during the single
aortic crossclamp period. Patients were weaned from cardiopul-
monary bypass and maintained on milrinone (loading dose: 0.5
g/kg in 15 minutes; infusion: 0.125-0.5 g · kg1 · min1) for
the first 12 hours postoperatively to maintain a cardiac index of 2.5
L · m2 · min or more in the latter part of the operative experience.
Patients received 1 to 6 coronary bypass grafts (mode of 3).
Fifty-four patients (95%) had at least 1 internal thoracic artery
used as a conduit, 8 of whom received bilateral internal thoracic
artery grafts. The aortic crossclamp and cardiopulmonary bypass
times were 61  19 and 97  27 minutes, respectively.
Radionuclide Ventriculography
Patients with an LVEF of 35% or less on RNVG, using isotope,
were enrolled in the study. Approximately 12 months after the
operation, 47 of the 49 surviving patients (96%) had RNVG for
reassessment of LVEF performed in the same institution as the
preoperative studies, using an identical protocol. All studies were
reported by observers blinded to the clinical details and other
investigational findings.
Thallium-201 Scintigraphy
All 57 patients underwent stress thallium-201 single-photon emis-
sion computed tomography (SPECT) before CABG. To provide
uniform reporting, 2 independent nuclear medicine physicians
reassessed all available studies during the first postoperative years.
Twenty studies were not available or technically satisfactory,
leaving 37 studies available for reanalysis. According to our pre-
viously published method to determine the presence and extent of
ischemic myocardium,12 18 had large defects, 13 had defects of
small to moderate size, and 6 had fixed perfusion defects.
Follow-up
All surviving patients were reviewed at 1 and 12 months postop-
eratively by an independent physician with no knowledge of
preoperative clinical status. The surviving patients were assessed
by clinical review or by telephone interview if they were unable to
travel. Telephone interviews were conducted by an experienced
research assistant. The clinical status, recurrence of symptoms,
repeat hospitalization, and cause of death were carefully docu-
mented. For missing patients, the Australian National Death Index
was used to track unrecorded deaths.
Outcome Assessment
The major end points of the study were all-cause mortality at 30
days, 12 months, and 10 years. These are expressed as “survival”
and “event-free survival.” Events were defined as: onset of Cana-
dian Cardiovascular Society (CCS) and/or New York Heart Asso-
ciation (NYHA) class III-IV, hospitalization for cardiac reasons,
and mitral valve surgery or transplantation. Functional class was
also assessed at 30 days, 12 months, and 10 years, angina using
CCS class and dyspnea using NYHA class. The effect of CABG on
LV function was assessed comparing preoperative and 12-month
RNVG measurements of LVEF.
Statistical Analysis
Continuous data were expressed as mean  1 SD. Survival was
evaluated univariately by Kaplan-Meier analysis and multivari-
ately by the Cox proportional hazards model. Variables considered
for analysis in predicting survival were age, sex, diabetes, myo-
cardial infarction, hypertension, peripheral vascular disease,
chronic obstructive pulmonary disease, CCS angina class, NYHA
functional class, LVEF, and perfusion defects on thallium scintig-
raphy.
Results
Fifty-seven patients entered the study, with the following
statistics: age, 67  8 years; LVEF, 0.28  0.04 (range
0.17-0.35); male sex, 53 (93%); diabetes, 9 (16%); hyper-
tension, 21 (37%); previous Q-wave myocardial infarction,
44 (77%); CCS class III-IV, 29 (50%); and NYHA class
III-IV, 37 (65%).
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Surgical Complications
All but 1 patient survived the operation and hospital admis-
sion, yielding an operative (inpatient 30-day) mortality of
1.7%. None of the patients had perioperative Q-wave myo-
cardial infarction. Three patients (5%) required insertion of
an intra-aortic balloon pump during the perioperative period
due to low cardiac output.
LV Function
Of the 49 patients who survived beyond 12 months after the
operation, 47 underwent repeat RNVG at a mean of 15  3
months postoperatively. Their mean LVEF postoperatively
(0.30  0.09) did not differ significantly from that before
operation (0.28  0.04; P  .09). In a subgroup of patients
who had large areas of reversible ischemia on thallium, the
LVEF improved by 0.1  0.04 (range: 0.05-0.21), rising
from 0.30  0.03 preoperatively to 0.40  0.05 postoper-
atively (P  .01).
Early Postoperative Outcome
Severe preoperative angina and heart failure symptoms
(classes III and IV), age at operation, presence of pathologic
Q-waves on surface electrocardiograms, and cardiothoracic
ratio on chest roentgenograms were examined in all pa-
tients. Findings of preoperative stress thallium-201 SPECT
were available in 37 patients.
By multivariate analyses, the adjusted odds ratio for
large reversible perfusion defects on preoperative stress
thallium-201 SPECT, for improved outcome for survival
and event-free survival at 15 months, was found to be 15
(95% confidence interval, 1.6-140, P  .03), indicating it to
be an independent predictor of an early outcome. None of
the other clinical variables were shown to have any predic-
tive value.
All-Cause Mortality
During the course of study over 10 years, there were 42
events (40 deaths and 2 transplants). The main causes of
death were heart failure in 12 (29%) patients, acute myo-
cardial infarction in 7 (17%), sudden death in 4 (10%), and
stroke in 3 (7%) (Figure 1). The survival in our study was
82.5% at 1 year, 55.7% at 5 years, and 23.9% at 10 years
(Figure 2).
According to the Cox proportional hazards model (Table
1), only male sex predicted improved long-term survival (P
 .04). NYHA class III-IV showed a trend toward reduced
long-term survival (Figure 3). Age, diabetes, and preoper-
ative myocardial infarction did not affect survival. EF did
not affect long-term survival (Figure 4). CCS class III-IV
(Figure 5) did not affect long-term survival. Large areas of
reversible ischemia on thallium, which is a predictor of
improved early outcome, did not affect survival (Figure 6).
Symptom-Free Survival
The overall symptom-free survival in our study population
was 77.2% at 1 year and 20.3% at 10 years. Preoperatively,
50% of patients were in CCS class III-IV; at 12 months,
94% (46/49) of the surviving patients were in CCS class 0-I.
At 10 years all the 11 surviving patients were in CCS class
0-I. Preoperatively, 65% of patients were in NYHA class
III-IV; at 12 months, 71% (35/49) of the survivors were in
NYHA class I. At 10 years all 11 surviving patients were in
class II.
Discussion
This is one of a handful of studies reported in the literature
examining the 10-year outcome of patients undergoing
myocardial revascularization for ischemic cardiomyopathy
and the only one that has been conducted prospectively.
Figure 1. Bar graph illustrating distribution of causes of death among 42 events (40 deaths, 2 transplants) over the
course of 10 years in 57 patients undergoing myocardial revascularization for ischemic cardiomyopathy. AMI, acute
myocardial infarction.
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Patients with unstable angina, myocardial infarction, and
other significant ischemic events within 4 weeks of the
study were specifically excluded. This was to minimize the
effects of myocardial stunning on postoperative changes in
contractile function.
Medical treatment alone for patients with coronary artery
disease and LV dysfunction has been associated with poor
results. Louie and colleagues5 reported 3-year survival of
25% in 54 patients (mean EF 22%), and Luciani and col-
leagues6 reported 5-year survival of 28% in 72 patients
(mean EF 21%). Currently end-stage ischemic heart disease
is one of the primary indications for heart transplantation
and accounts for 40% to 50% of procedures performed.
Only 10% of eligible patients undergo transplantation and
many die on the waiting list17 because of limited donor
availability.18 The present study demonstrates that myocar-
dial revascularization can be offered to patients with isch-
emic LV dysfunction at a low operative risk (1.7%) but is
associated with poor long-term survival.
The low operative mortality (1.7%) is in line with the
estimates from other authors.13,19-21 Early cardiac morbidity
was low with no perioperative myocardial infarction and
Figure 2. Survival and 95% confidence limits of 57 patients.
TABLE 1. Predictors of survival: Cox proportional hazards model
Variables Rate ratio 95% CI P value
Sex (male versus female) 0.54 0.31-0.96 .04
Age (x versus x  10 years)* 0.76 0.49-1.19 .2
Diabetes 0.79 0.30-2.10 .6
Previous MI 0.41 0.15-1.16 .2
Hypertension 0.60 0.28-1.32 .2
PVD 0.33 0.06-1.69 .2
COPD 1.12 0.28-4.38 .9
CCS angina class
(3/4 versus 1/2)
1.15 0.81-1.62 .4
NYHA functional class
(3/4 versus 1/2)
1.42 0.97-2.07 .07
LVEF % (x versus x  10)* 1.17 0.56-2.44 .7
5 viable segments on thallium 0.45 0.17-1.18 .1
CI, Confidence interval; MI, myocardial infarction; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; CCS, Canedian
Cardiovascular Society; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.
*x versus x  10 years compares actual number versus actual number minus 10.
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use of intra-aortic balloon pumping in only 5% of patients.
Other recent developments such as off-pump surgery or
pump-assisted CABG might improve perioperative out-
comes in this high-risk group of patients.22
The most common cause of death was heart failure,
similar to other recent studies,16,18,19,21 and over half the
deaths were due to noncardiac causes. The 5-year survival
of 55% is slightly lower than those in other studies.13,19,21
The differences may be due to estimated survivals used in
the other studies. No previous studies have described com-
plete 10-year survival results.15 A 20-year survival study
from the Emory group showed that low ejection fractions
independently predicted poor long-term survival after
CABG despite good relief of angina.23
Figure 3. Baseline NYHA class III-IV versus I-II and survival.
Figure 4. Baseline ejection fraction (<25%, 25%-29%, and 30%-35%) and survival.
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Male sex was the only variable associated with good
long-term survival similar to another report.19 Age and
NYHA class did not affect long-term survival, unlike other
studies.16,18,19,21 NYHA class III-IV did show a trend to-
ward poor long-term survival. CCS class III-IV was asso-
ciated with a trend toward better survival throughout the
course of study, although not statistically significant. This
could be explained by higher CCS class, possibly being
associated with larger areas of reversible ischemic myocar-
dium.
Few studies have provided details of functional out-
comes after operation. In patients with chronic heart failure,
functional capacity has very little relationship to LVEF.4
Early reports of revascularization have suggested that im-
provement in LVEF might be an index of successful func-
tional outcome.5,6,11,24-26 However, more recent reports
clearly show that an increase in LVEF is not necessarily
associated with clinical improvement as measured by
NYHA, exercise capacity, or quality-of-life scores.12,27-30
Our study also showed no significant increase in LVEF at a
mean of 15 months postoperatively, except in a subgroup of
patients with large areas of viable myocardium on thallium.
However, extensive preoperative reversible ischemia did
not predict a greater improvement in functional class at 15
months, despite the prediction of improved survival and
event-free survival.
Symptom-free survival (from heart failure symptoms) of
20% at 10 years is low. The de novo appearance, recurrence,
or persistence of heart failure symptoms may indicate the
relentless progress toward LV insufficiency. Most of our
patients were free from angina during the course of study,
similar to recently reported studies,20,22 and compared fa-
Figure 5. Baseline CCS class III-IV versus I-II and survival.
Figure 6. Relationship between viability on preoperative thallium-201 scintigraphy and survival.
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vorably to the studies by Trachiotis and colleagues13 (40%
at 5.8 years) and Kaul and coworkers10 (35% at 3.6 years).
One of the important outcomes was that nearly all the
10-year survivors were symptom-free.
Limitations
The current study does not have a parallel control group of
patients treated medically to determine which fared better.
The symptomatic follow-up was incomplete between 12
months and 10 years. Nearly all patients were operated on
more than 10 years ago and hence the possible additional
effects of newly evolving surgical procedures, such as LV
reconstructive surgery and mitral valve repair, were un-
known. During the progress of this study, there have been
major advances in medical management of chronic heart
failure, especially blockade of renin-angiotension and sym-
pathetic nervous system.3,31,32 In the absence of regular
RNVG to assess LVEF and regular coronary angiograms to
access graft patency, it is difficult to determine whether the
poor late outcome was a result of progressive LV dysfunc-
tion, bypass graft disease, or other factors.
Conclusion
Myocardial revascularization for ischemic cardiomyopathy
can be performed relatively safely with low operative mor-
tality. It has the advantage of preserving the LV function at
15 months. It is associated with good functional relief,
especially from angina and, to a lesser extent, from heart
failure symptoms. However, long-term mortality still re-
mains high. It is possible that additional strategies such as
LV reconstructive surgery and current optimal medical ther-
apy could further improve this outlook.
We acknowledge the help of Meg Storer, RN, BN(Hons),
GrdCert (Cardio Thoracic).
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